Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition - an ESE clinical practice guideline
AuthorsHusebye, E. S.
Higham, Claire E
Paschou, S. A.
van der Kooij, M.
Dekkers, O. M.
AffiliationE Husebye, University of Bergen, Department of Clinical Science, Bergen, Norway
MetadataShow full item record
AbstractImmune checkpoint inhibitors (ICI) have revolutionized cancer treatment, but are associated with significant autoimmune endocrinopathies that pose both diagnostic and treatment challenges. The aim of this guideline is to provide clinicians with the best possible evidence-based recommendations for treatment and follow-up of patients with ICI-induced endocrine side effects based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. As these drugs have been used a relatively short time, large systematic investigations are scarce. A systematic approach to diagnosis, treatment and follow-up is needed, including baseline tests of endocrine function before each treatment cycle. We conclude that there is no clear evidence for the benefit of high-dose glucocorticoids to treat endocrine toxicities with the possible exceptions of severe thyroid eye disease and hypophysitis affecting the visual apparatus. With the exception of thyroiditis, most endocrine dysfunctions appear to be permanent regardless of ICI discontinuation. Thus, the development of endocrinopathies does not dictate a need to stop ICI treatment.
CitationHusebye ES, Castinetti F, Criseno S, Curigliano G, Decallonne B, Fleseriu M, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition - an ESE clinical practice guideline. Eur J Endocrinol. 2022 Sep 1. PubMed PMID: 36149449. Epub 2022/09/24. eng.
JournalEuropean Journal of Endocrinology
- The side effects of immune checkpoint inhibitor therapy on the endocrine system.
- Authors: Goyal I, Pandey MR, Sharma R, Chaudhuri A, Dandona P
- Issue date: 2021 Apr
- [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
- Authors: Santos MJ
- Issue date: 2022 Mar 2
- How we treat endocrine complications of immune checkpoint inhibitors.
- Authors: Paschou SA, Stefanaki K, Psaltopoulou T, Liontos M, Koutsoukos K, Zagouri F, Lambrinoudaki I, Dimopoulos MA
- Issue date: 2021 Feb
- Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
- Authors: Zhai Y, Ye X, Hu F, Xu J, Guo X, Zhuang Y, He J
- Issue date: 2019 Nov 6
- Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
- Authors: González-Rodríguez E, Rodríguez-Abreu D, Spanish Group for Cancer Immuno-Biotherapy (GETICA)
- Issue date: 2016 Jul